Finally, SL biosynthesis represents a gold mine for new drug targets alongside at least two axes, de novo synthesis and salvage and remodelling. On one hand, the protozoan de novo SL biosynthetic pathway comprises three key steps, and considering their divergence compared with the mammalian host, identifying specific inhibitors for those could open an opportunity for anti-protozoal drugs with synergistic effects and lower incidences of resistance. On the other hand, the nature of obligate intracellular parasites dictates that further efforts should be directed towards the catabolic/salvage pathway where parasite–host dependencies could be exploited in order to identify additional key steps, or host enzymes, where inhibitors would exert further synergism with the de novo inhibitors.